This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Group Wants Boxed Warning On Constipation Drug

WASHINGTON (AP) ¿ Consumer advocates are calling on the Food and Drug Administration to add stronger warning labels about risks for pregnant women related to a constipation drug.

The FDA has approved Amitiza to treat chronic constipation and irritable bowel syndome, and it was prescribed more than 1 million times last year. The drug is marketed by Sucampo Pharmaceuticals Inc. and Takeda Pharmaceuticals Co.

The label warns that the pills have not been studied in pregnant women and that mothers-to-be should use the drug only "if the potential benefits justify the potential risk to the fetus." But Public Citizen says that note isn't good enough.

The consumer watchdog group filed a petition with the FDA on Wednesday demanding the drug receive a "black box" warning, the strongest type available.

The group's petition points out that a chemically similar drug called misoprostol carries the boxed warning, stating that it can cause "abortion and premature birth." That drug, marketed by Pfizer Inc. as Cytotec, is approved to treat gastric ulcers, but is used off-label to hasten labor or cause an abortion, according to Public Citizen.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PFE $33.24 0.00%
SCMP $18.19 0.00%
AAPL $112.12 0.00%
FB $93.24 0.00%
GOOG $643.61 0.00%


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs